Portland, OR -- (SBWire) -- 06/12/2018 --Diabetic Retinopathy Market was valued at $966 million in 2015, and is expected to reach $2,490 million by 2022, supported by a CAGR of 14.4% during the forecast period 2014 to 2022. Diabetic retinopathy (DR) is an eye disease associated with diabetic patients. The disease occurs when there is damage to the retina due to diabetes. Without timely treatment, the disease may lead to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population; eventually leading to blindness.

Get sample copy of this report: https://www.alliedmarketresearch.com/request-sample/2010

Top Dominating Key Players:

- Boehringer Ingelheim GmbH
- KOWA Company, Ltd
- BCN Peptides S.A.
- ThromboGenics NV.

The diabetic retinopathy market is expected to witness significant growth during the forecast period due to factors such as increase in prevalence of diabetes, growth in geriatric population, rise in incidence of blindness due to diabetes, and augment in focus on awareness, which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs can pose as a major obstacle for the growth of the diabetic retinopathy market. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are anticipated to provide several opportunities for the market growth.

The use of therapeutics for the treatment of diabetic retinopathy is expected to increase in the near future, owing to high prevalence of diabetes coupled with rise in geriatric population. There are significant advancements in diabetic retinopathy treatment therapies for disease management. Asia-Pacific and LAMEA regions are expected to offer lucrative opportunities to market players, due to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of diabetic retinopathy.

Make purchase enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/2010

North America accounted for majority of the share (nearly two-fifths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of diabetes along with the rise in geriatric population, increased patient awareness about diabetic retinopathy, and favorable reimbursement framework for retinopathy procedures. In addition, presence of highly sophisticated healthcare infrastructure is anticipated to provide new growth opportunities for the key players in this market.

Some Key Benefits

- This report provides an extensive analysis of the current and emerging market trends and dynamics in the global diabetic retinopathy market.

- Comprehensive analysis of geographical regions is provided to determine the prevailing opportunities in the market.

- This study provides the competitive landscape of the market to predict the competitive environment across geographies.

- This report entails the detailed quantitative analysis of the current market and estimations from 2014 to 2022 to identify the prevailing opportunities.

Have questions? Speak with our analyst @ https://www.alliedmarketresearch.com/connect-to-analyst/2010